Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allergan's Restasis Defense Falters As PTAB Dismisses Tribal Immunity Ploy

Executive Summary

The damage inflicted by Mylan and other manufacturers looking to sell Restasis generics already has been felt by Allergan, but the PTAB dealt the dry eye drug's patent defense another blow by rejecting the Mohawk Tribe's plea to have an inter partes review thrown out.

Related Content

Takeda's Interest Likely To Flush Out Further Shire Suitors
Stock Scan February 2018: Wet But Above Water
Allergan Touts Ubrogepant Phase III Success, But Liver Tox Concerns Overhang
Allergan Loses Another Battle, But War To Block Restasis Generics Continues
J.P. Morgan Notebook Day 1: Tax Reform At Last, Allergan's Job Cuts, Teva Turnaround, Biogen's Cash, And Getting FDA-Friendly
Allergan Readies Cost Cuts As Restasis Generics Approach
Allergan May Rue Mohawk Tribe Deal As Court Invalidates Restasis Patents
Allergan Shifts Restasis Patents To Native American Tribe To Invoke Immunity From IPR


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts